Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nilotinib + cetuximab
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Nilotinib + cetuximab is an investigational combination therapy involving two distinct anticancer agents. Nilotinib is a small molecule tyrosine kinase inhibitor primarily targeting BCR-ABL, KIT, and PDGFR kinases. It is approved for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML), including cases resistant to imatinib. Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved for use in metastatic colorectal cancer and head and neck squamous cell carcinoma. The rationale for combining these drugs lies in their complementary mechanisms—nilotinib inhibits intracellular signaling pathways critical to cancer cell proliferation, while cetuximab blocks EGFR-mediated signaling at the cell surface. This combination has been studied in early-phase clinical trials to determine safety and efficacy in solid tumors[2][3][6].
- Other names
- nilotinib + cetuximabnilotinibcetuximab
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)EGFR (Epidermal growth factor receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFR (PDGFR family)
Beyond the preview
Go deeper on nilotinib + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nilotinib + cetuximab.